leishmaniasis
Information
- Disease name
- leishmaniasis
- Disease ID
- DOID:9065
- Description
- "A parasitic protozoa infectious disease that involves infection caused by protozoan parasite of the genus Leishmania, which is transmitted by the bite of sand fly (subfamily Phlebotominae)." [url:http\://www.cdc.gov/ncidod/dpd/parasites/leishmania/factsht_leishmania.htm]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02530697 | Active, not recruiting | Phase 2 | The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil | August 2015 | August 2026 |
| NCT00004755 | Completed | Phase 2 | Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil | September 1995 | |
| NCT00373568 | Completed | Phase 1/Phase 2 | Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis | April 2005 | December 2007 |
| NCT00373776 | Completed | Phase 1/Phase 2 | Miltefosine for Mucosal Leishmaniasis | April 2004 | May 2006 |
| NCT00401297 | Completed | Th1/Th2 Polarization and Linkage to L. Viannia Infection Outcomes | December 2006 | April 2010 | |
| NCT00401349 | Completed | Expression of Mif Alleles in Individuals With Leishmaniasis | December 2006 | April 2010 | |
| NCT00401557 | Completed | Mechanisms Relating to the Distinct in Vitro Susceptibility of Human Macrophages to L. Viannia Infection | December 2006 | April 2010 | |
| NCT00657618 | Completed | Phase 1/Phase 2 | Use of Sodium Stibogluconate as a Treatment for Leishmaniasis | October 2004 | April 2015 |
| NCT00662012 | Completed | Phase 2 | Sodium Stibogluconate Treatment of Leishmaniasis | June 2002 | December 2007 |
| NCT01300975 | Completed | Phase 2 | Intralesional Antimony for Bolivian Cutaneous Leishmaniasis | January 2011 | July 2012 |
| NCT01377974 | Completed | Phase 2 | Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis | July 2009 | December 2014 |
| NCT00001169 | Completed | Clinical Investigation of Infections Due to Leishmanial Parasites | December 1979 | February 2001 | |
| NCT01484548 | Completed | Phase 1 | Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers | January 2012 | May 2013 |
| NCT01751048 | Completed | Phase 1 | LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine | March 2013 | January 2015 |
| NCT02656797 | Completed | Phase 2 | Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis | January 30, 2018 | October 1, 2021 |
| NCT03294161 | Completed | Phase 2 | Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis | December 2014 | June 2017 |
| NCT03641339 | Completed | N/A | Defining Skin Immunity of a Bite of Key Insect Vectors in Humans | September 5, 2018 | May 20, 2020 |
| NCT03993093 | Completed | Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre | June 1, 2019 | March 15, 2020 | |
| NCT04504435 | Completed | Phase 1 | Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants | September 29, 2020 | January 11, 2024 |
| NCT04512742 | Completed | N/A | A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies | October 16, 2021 | November 1, 2023 |
| NCT05449717 | Recruiting | Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan | May 31, 2022 | May 31, 2026 | |
| NCT00344188 | Recruiting | Diagnosis and Treatment of Leishmania Infections | November 30, 2001 | ||
| NCT03784248 | Recruiting | Mediterranean Visceral Leishmaniasis With Leishmania Infantum | July 3, 2019 | August 15, 2024 | |
| NCT06307171 | Recruiting | N/A | Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers | May 22, 2023 | November 2026 |
| NCT06124144 | Terminated | Phase 1 | Safety and Drug Absorption of Orally Administered Oleylphosphocholine (OlPC) in Healthy Adults | June 21, 2023 | February 27, 2024 |
| NCT03874234 | Terminated | Phase 1 | Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects | April 30, 2019 | October 17, 2019 |
| NCT03009422 | Unknown status | N/A | Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis. | November 2014 | June 2017 |
| NCT02429505 | Withdrawn | Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry | July 2015 | March 2020 | |
| NCT01437020 | Withdrawn | Phase 1/Phase 2 | SCH708980 With and Without AmBisome for Visceral Leishmaniasis |
- Disase is a (Disease Ontology)
- DOID:2789
- Cross Reference ID (Disease Ontology)
- GARD:6881
- Cross Reference ID (Disease Ontology)
- ICD10CM:B55
- Cross Reference ID (Disease Ontology)
- ICD9CM:085
- Cross Reference ID (Disease Ontology)
- MESH:D007896
- Cross Reference ID (Disease Ontology)
- NCI:C34767
- Cross Reference ID (Disease Ontology)
- ORDO:507
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:266206004
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0023281
- Disase Synonym (Disease Ontology)
- Post Kala-Azar Dermal Leishmaniasis
- Disase Synonym (Disease Ontology)
- post-kala-azar dermal infectious disease by leishmaniasis
- Disase Synonym (Disease Ontology)
- Post-kala-azar dermal leishmaniasis
- OrphaNumber from OrphaNet (Orphanet)
- 507
- ICD10 preferred id (Insert disease from ICD10)
- D0000741
- ICD10 class code (Insert disease from ICD10)
- B55
- MeSH unique ID (MeSH (Medical Subject Headings))
- D007896